Mereo BioPharma Group (MREO) Projected to Post Quarterly Earnings on Tuesday

Mereo BioPharma Group (NASDAQ:MREO) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Mereo BioPharma Group to post earnings of $0.02 per share and revenue of $11.6670 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 2:00 AM ET.

Mereo BioPharma Group (NASDAQ:MREO) last issued its quarterly earnings data on Friday, March 20th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mereo BioPharma Group Stock Performance

Mereo BioPharma Group stock traded down $0.01 during midday trading on Tuesday, reaching $0.28. 576,373 shares of the company were exchanged, compared to its average volume of 6,850,136. The company has a market capitalization of $44.69 million, a price-to-earnings ratio of -4.67 and a beta of 0.24. The firm’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.99. Mereo BioPharma Group has a 1 year low of $0.20 and a 1 year high of $3.05.

Institutional Trading of Mereo BioPharma Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtus Investment Advisers LLC grew its holdings in Mereo BioPharma Group by 199.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 122,595 shares of the company’s stock valued at $51,000 after buying an additional 81,665 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Mereo BioPharma Group during the 4th quarter valued at $106,000. Quadrature Capital Ltd purchased a new stake in shares of Mereo BioPharma Group during the 4th quarter valued at $111,000. Balyasny Asset Management L.P. purchased a new stake in shares of Mereo BioPharma Group during the 4th quarter valued at $533,000. Finally, Logos Global Management LP grew its stake in shares of Mereo BioPharma Group by 270.0% during the 4th quarter. Logos Global Management LP now owns 1,850,000 shares of the company’s stock valued at $771,000 after buying an additional 1,350,000 shares during the period. Hedge funds and other institutional investors own 62.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MREO shares. Needham & Company LLC decreased their price target on shares of Mereo BioPharma Group from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Mereo BioPharma Group in a research note on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mereo BioPharma Group in a research note on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and issued a $1.00 price objective on shares of Mereo BioPharma Group in a research report on Friday, January 16th. Finally, Lifesci Capital raised Mereo BioPharma Group to a “hold” rating in a research report on Thursday, March 19th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mereo BioPharma Group presently has a consensus rating of “Hold” and an average target price of $3.25.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc is a clinical?stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset?centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.